CONTRIBUTORS

Neuro-ophthalmology p. 1188-1191 October 2019, Vol.25, No.5 doi: 10.1212/01.CON.0000603852.42847.46
CONTRIBUTORS
BROWSE ARTICLES

Marc Dinkin, MD Guest Editor

Associate Professor, Departments of Neurology, Ophthalmology, and Neurosurgery; Director of Neuro-ophthalmology, Weill Cornell Medical College, New York, New York

Relationship Disclosure: Dr Dinkin serves as an associate editor for the Journal of Neuro-Ophthalmology and as an editor for Practical Neurology and has received compensation for travel for speaking engagements from The American Austrian Foundation and research/grant support from the Helen and Robert Apel Foundation. Dr Dinkin has provided depositions and expert testimony on medicolegal cases involving idiopathic intracranial hypertension, ischemic optic neuropathy, and head trauma.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Dinkin discusses the unlabeled/investigational use of azathioprine for cancer-associated retinopathy; corticosteroids for bilateral diffuse uveal melanocytic proliferation, cancer-associated retinopathy, melanoma-associated retinopathy, opsoclonus-myoclonus syndrome, and paraneoplastic optic neuropathy; IV immunoglobulin (IVIg) for cancer-associated retinopathy, melanoma-associated retinopathy, and opsoclonus-myoclonus syndrome; lenalidomide for POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes); mycophenolate mofetil for cancer-associated retinopathy and paraneoplastic optic neuropathy; and rituximab for cancer-associated retinopathy.

Jeffrey L. Bennett, MD, PhD, FAAN

Gertrude Gilden Professor for Neurodegenerative Disease Research, Professor of Neurology, Ophthalmology, and Immunology Program in Neuroscience, University of Colorado School of Medicine, Aurora, Colorado

Relationship Disclosure: Dr Bennett serves on the editorial boards of the Journal of Neuro-Ophthalmology, Multiple Sclerosis, and Neurology: Neuroimmunology & Neuroinflammation and as a consultant for AbbVie Inc; Alexion; Chugai Pharmaceutical Co, Ltd; Clene Nanomedicine; EMD Serono, Inc; Equillium, Inc; Frequency Therapeutics; Genentech, Inc; MedImmune; and Sanofi Genzyme. Dr Bennett has received research/grant support from EMD Serono, Inc; the Guthy-Jackson Charitable Foundation; Mallinckrodt Pharmaceuticals; the National Eye Institute (R01EY022936); the National Institute of Allergy and Infectious Diseases (UM1AI110498); and Novartis AG. Dr Bennett receives publishing royalties from UpToDate, Inc, and has received personal compensation for serving as a medicolegal consultant on medical cases involving neuroinflammatory and neuro-ophthalmologic disorders.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Bennett discusses the unlabeled/investigational use of plasma exchange and apheresis for the treatment of optic neuritis.

Marc A. Bouffard, MD

Instructor in Neurology, Harvard Medical School; Codirector of Neuro-Ophthalmology, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Relationship Disclosure: Dr Bouffard serves as a consultant for the US Department of Justice Vaccine Injury Compensation Program.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Bouffard reports no disclosure.

Fiona Costello, MD, FRCPC

Associate Professor, Departments of Clinical Neurosciences and Surgery, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Relationship Disclosure: Dr Costello has served on advisory boards for Frequency Therapeutics and Alexion Canada and receives research/grant support from the Hotchkiss Brain Institute and the MS Research Program.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Costello reports no disclosure.

Eric R. Eggenberger, DO, FAAN

Professor of Ophthalmology, Neurology, and Neurosurgery, Mayo Clinic College of Medicine and Science, Jacksonville, Florida

Relationship Disclosure: Dr Eggenberger reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Eggenberger reports no disclosure.

Christopher C. Glisson, DO, MS, FAAN

Medical Director, Neuro-Ophthalmology, Mercy Health Hauenstein Neurosciences, Grand Rapids, Michigan; Assistant Professor, Department of Neurology and Ophthalmology, Michigan State University, East Lansing, Michigan

Relationship Disclosure: Dr Glisson reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Glisson reports no disclosure.

Lynn Gordon, MD, PhD

Professor of Ophthalmology, Stein Eye Institute; Senior Associate Dean, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California

Relationship Disclosure: Dr Gordon serves on the board of trustees of the American Academy of Ophthalmology and on the editorial boards of Ophthalmology Retina, Ocular Immunology and Inflammation, and the Journal of Neuro-Ophthalmology. Dr Gordon receives licensing fees from the University of California Los Angeles for epithelial membrane protein 2.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Gordon discusses the unlabeled/investigational use of azathioprine for cancer-associated retinopathy; corticosteroids for bilateral diffuse uveal melanocytic proliferation, cancer-associated retinopathy, melanoma-associated retinopathy, opsoclonus-myoclonus syndrome, and paraneoplastic optic neuropathy; IV immunoglobulin (IVIg) for cancer-associated retinopathy, melanoma-associated retinopathy, and opsoclonus-myoclonus syndrome; lenalidomide for POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes); mycophenolate mofetil for cancer-associated retinopathy and paraneoplastic optic neuropathy; and rituximab for cancer-associated retinopathy.

Mark J. Morrow, MD, FAAN

Chair, Department of Neurology, Harbor-University of California Los Angeles Medical Center; Clinical Professor of Neurology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California

Relationship Disclosure: Dr Morrow reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Morrow discusses the unlabeled/investigational use of medications for the treatment of ischemic optic neuropathy, none of which are approved by the US Food and Drug Administration.

Heather E. Moss, MD, PhD, FAAN

Assistant Professor of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, California; Assistant Professor of Neurology and Neurological Sciences, Stanford University, Stanford, California

Relationship Disclosure: Relationship Disclosure: Dr Moss serves on the board of directors of the North American Neuro-Ophthalmology Society and as a review editor for Current Eye Research, an associate editor for Frontiers in Neurology, a section editor for the Journal of Neuro-Ophthalmology, and a special section editor for Neuro-Ophthalmology. Dr Moss receives research/grant support from the Myelin Repair Foundation, the National Institutes of Health/National Eye Institute (K23 EY024345, P30 EY 026877), and Research to Prevent Blindness and publishing royalties from Elsevier. Dr Moss has served as a legal consultant providing record review and deposition on neuro-ophthalmic diseases.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Moss reports no disclosure.

Cristiano Oliveira, MD

Assistant Professor of Ophthalmology, Weill Cornell Medicine, New York, New York

Relationship Disclosure: Dr Oliveira reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Oliveira discusses the unlabeled/investigational use of gene therapy and idebenone for Leber hereditary optic neuropathy.

Sashank Prasad, MD

Associate Professor of Neurology, Harvard Medical School; Director, Harvard Brigham and Women’s Hospital–Massachusetts General Hospital Neurology Residency; Chief, Division of Neuro-ophthalmology, Brigham and Women’s Hospital, Boston, Massachusetts

Relationship Disclosure: Dr Prasad serves as an associate editor for the Journal of Neuro-Ophthalmology, receives publishing royalties from McGraw-Hill, and has provided expert medicolegal opinion on legal cases involving idiopathic intracranial hypertension, ischemic optic neuropathy, and traumatic brain injury.

Unlabeled/Investigational Use Disclosure: Dr Prasad reports no disclosure.

Janet C. Rucker, MD

Bernard A. and Charlotte Marden Professor of Neurology; Professor of Ophthalmology, New York University School of Medicine, New York, New York

Relationship Disclosure: Dr Rucker reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Rucker discusses the unlabeled/investigational use of medications for the management of abnormal eye movements, none of which are approved by the US Food and Drug Administration.

James N. Scott, MD, MSc

Clinical Associate Professor, Departments of Diagnostic Imaging and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Relationship Disclosure: Dr Scott reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Scott reports no disclosure.

Matthew J. Thurtell, MBBS, MSc, FRACP

Associate Professor of Ophthalmology and Neurology; Director of Neuro-ophthalmology, University of Iowa, Iowa City, Iowa

Relationship Disclosure: Dr Thurtell serves on the editorial board of the Journal of Neuro-Ophthalmology, receives research/grant support from the National Eye Institute (U10-EY025990), and receives book royalties from Oxford University Press.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Thurtell discusses the unlabeled/investigational use of acetazolamide, furosemide, methazolamide, and topiramate for the treatment of idiopathic intracranial hypertension.

Self-Assessment and CME Test Writers

Douglas J. Gelb, MD, PhD, FAAN

Professor of Neurology, University of Michigan, Ann Arbor, Michigan

Relationship Disclosure: Dr Gelb receives royalties from MedLink, Oxford University Press, and UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Gelb reports no disclosure.

James W. M. Owens Jr, MD, PhD

Associate Professor of Neurology, Adjunct Associate Professor of Pediatrics, University of Washington School of Medicine, Seattle, Washington

Relationship Disclosure: Dr Owens serves as CME co-editor for Neurology and receives publishing royalties from UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Owens reports no disclosure.

© 2019 American Academy of Neurology.